Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463814 · ClinicalTrials.gov registry record · Phase 1
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
A Phase 1 study of Cancer and Tumor, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 4
- Study locations
NCT00463814: Active Phase 1 study of Cancer and Tumor, sponsored by AstraZeneca.
NCT00463814 is a Phase 1 study of Cancer and Tumor that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 58 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00463814, a Phase 1 study of Cancer and Tumor, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at
Interventions
- DRUG AZD6244
Study Locations (4)
Other
- Research Site - Nijmegen
- Research Site - Utrecht
- Research Site - Sutton
Colorado
- Research Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-03-08 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What the registry record for NCT00463814 still lists
NCT00463814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD6244 is the first listed.
NCT00463814 reports a single indexed study location in Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT00463814 about?
NCT00463814 is a clinical study titled "AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies". The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
What is the current status of trial NCT00463814?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2007-03-08. Estimated completion is 2025-12-31.
What conditions does trial NCT00463814 study?
This clinical trial studies the following conditions: Cancer, Tumor.
What interventions are being tested in trial NCT00463814?
The interventions under investigation include: AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00463814?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00463814 being conducted?
This trial has 4 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00463814's enrollment target sits among peer trials
58 410th of 615 higher than 206 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI